DELX (Delex Healthcare Group) Debt-to-EBITDA : N/A (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Delex Healthcare Group Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Delex Healthcare Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. Delex Healthcare Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. Delex Healthcare Group's annualized EBITDA for the quarter that ended in Sep. 2023 was $0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Delex Healthcare Group's Debt-to-EBITDA or its related term are showing as below:

DELX's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.58
* Ranked among companies with meaningful Debt-to-EBITDA only.

Delex Healthcare Group  (OTCPK:DELX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Delex Healthcare Group Debt-to-EBITDA Related Terms


Delex Healthcare Group Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Delex Healthcare Group's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Delex Healthcare Group Debt-to-EBITDA Chart

Delex Healthcare Group Annual Data
Trend
Debt-to-EBITDA

Delex Healthcare Group Semi-Annual Data
Sep22 Sep23
Debt-to-EBITDA N/A N/A

DELX vs PIAC, PWM, BHV: Debt-to-EBITDA Comparison

For the Drug Manufacturers - General subindustry, Delex Healthcare Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Delex Healthcare Group Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Delex Healthcare Group's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Delex Healthcare Group's Debt-to-EBITDA falls into.



Delex Healthcare Group Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Delex Healthcare Group's Debt-to-EBITDA for the fiscal year that ended in . 20 is calculated as

Delex Healthcare Group's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is one times the quarterly (Sep. 2023) EBITDA data.


Delex Healthcare Group Business Description

Address Carnation Street, Blk 4, Lot 4, Cor., Magnolia, Novaliches, Quezon City, PHL, 1109
Delex Healthcare Group Inc is a healthcare-focused organization engaged in pharmaceutical and healthcare-related businesses.